Skip Navigation


Rheumatology Advance Access originally published online on May 11, 2007
Rheumatology 2007 46(7):1049-1051; doi:10.1093/rheumatology/kem106
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/7/1049    most recent
kem106v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shenker, N. G.
Right arrow Articles by Jawad, A. S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shenker, N. G.
Right arrow Articles by Jawad, A. S. M.
Related Collections
Right arrow Osteoporosis and Metabolic Bone Disease
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

Bisphosphonates and osteonecrosis of the jaw

N. G. Shenker and A. S. M. Jawad

Department of Rheumatology, The Royal London Hospital, Bancroft Road, London E1 4DG, UK

Correspondence to: Dr Nicholas G Shenker, E-mail: mpxns@bath.ac.uk; alismjawad1@hotmail.com

The first 150 words of the full text of this article appear below.

There are concerns regarding osteonecrosis of the jaw (ONJ) in patients who take aminobisphosphonates. This is a relatively newly recognized complication of a therapy from which hundreds of thousands of patients in the UK currently benefit, a number which is currently increasing. What is the evidence linking these drugs with ONJ? Which bisphosphonates are implicated? What patients are at risk? And finally, what are the implications of this new insight for the management and safety of patients under the care of rheumatologists?

ONJ is a rare but often intractable disease. Patients with ONJ present with exposed bone related to the oral cavity which is necrotic and often complicated by secondary infection with the bacteria that typically cause periodontitis, including actinomycetes [1]. Patients usually present in pain which is sometimes severe although a significant proportion, up to a third, have no pain at all [2]. Other manifestations . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
N. G. Shenker and A. S. M. Jawad
Comment on: Bisphosphonates and osteonecrosis of the jaw: reply
Rheumatology, March 1, 2008; 47(3): 383 - 384.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. L. Bianchi, C. Limonta, J. Frasunkiewicz, M. Biggioggero, and S. Vai
Comment on: Bisphosphonates and osteonecrosis of the jaw
Rheumatology, March 1, 2008; 47(3): 383 - 383.
[Full Text] [PDF]